← Patent-cliff monitor small molecule JARDIANCE EMPAGLIFLOZIN
Loss of exclusivity December 2034 latest FDA-listed patent expiry
Drug detail Brand name JARDIANCE Active ingredient EMPAGLIFLOZIN Strength 10MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval August 2014 Marketing status RX
Listed patents Patent Expires Type 9949998*PED December 2034 — 9949997*PED November 2034 — 11090323*PED October 2034 — 10258637*PED October 2034 — 12433906*PED October 2034 — 11813275*PED October 2034 — 11833166*PED October 2034 — 9949998 June 2034 use U-2290 9949997 May 2034 use U-3199 12263153 April 2034 use U-4171 11666590 April 2034 use U-3691 11833166 April 2034 use U-3777 11813275 April 2034 use U-3760 12433906 April 2034 use U-4296 11090323 April 2034 use U-3191 12427162 April 2034 use U-4287 10258637 April 2034 use U-2290 12527810*PED October 2033 — 12527810 April 2033 use U-4403 12115179*PED August 2030 — 8551957*PED April 2030 — 12115179 February 2030 use U-4023 8551957 October 2029 use U-1651 7579449*PED February 2029 — 7579449 August 2028 substance 7713938*PED October 2027 — 7713938 April 2027 substance, product
Regulatory exclusivity Code Expires PED December 2026 I-922 September 2026 NPP June 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.